nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA2—myometrium—uterine cancer	0.0121	0.045	CbGeAlD
Lithium—IMPA1—renal system—uterine cancer	0.0117	0.0437	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—uterine cancer	0.0105	1	CbGdCrCtD
Lithium—GSK3A—myometrium—uterine cancer	0.0103	0.0384	CbGeAlD
Lithium—IMPA2—uterine cervix—uterine cancer	0.00941	0.035	CbGeAlD
Lithium—IMPA1—female reproductive system—uterine cancer	0.00939	0.035	CbGeAlD
Lithium—GSK3B—epithelium—uterine cancer	0.00931	0.0347	CbGeAlD
Lithium—GSK3B—uterine cervix—uterine cancer	0.00923	0.0344	CbGeAlD
Lithium—GSK3B—smooth muscle tissue—uterine cancer	0.00897	0.0334	CbGeAlD
Lithium—IMPA2—decidua—uterine cancer	0.00896	0.0334	CbGeAlD
Lithium—IMPA2—renal system—uterine cancer	0.0088	0.0328	CbGeAlD
Lithium—GSK3B—decidua—uterine cancer	0.00879	0.0327	CbGeAlD
Lithium—GSK3B—renal system—uterine cancer	0.00863	0.0322	CbGeAlD
Lithium—IMPA1—female gonad—uterine cancer	0.00855	0.0318	CbGeAlD
Lithium—IMPA2—endometrium—uterine cancer	0.00851	0.0317	CbGeAlD
Lithium—IMPA2—mammalian vulva—uterine cancer	0.00823	0.0307	CbGeAlD
Lithium—GSK3A—uterine cervix—uterine cancer	0.00802	0.0299	CbGeAlD
Lithium—GSK3A—smooth muscle tissue—uterine cancer	0.0078	0.029	CbGeAlD
Lithium—GSK3B—uterus—uterine cancer	0.00769	0.0286	CbGeAlD
Lithium—GSK3A—decidua—uterine cancer	0.00765	0.0285	CbGeAlD
Lithium—GSK3A—renal system—uterine cancer	0.00751	0.028	CbGeAlD
Lithium—GSK3A—endometrium—uterine cancer	0.00726	0.027	CbGeAlD
Lithium—IMPA2—female reproductive system—uterine cancer	0.00705	0.0262	CbGeAlD
Lithium—GSK3A—mammalian vulva—uterine cancer	0.00702	0.0261	CbGeAlD
Lithium—GSK3B—female reproductive system—uterine cancer	0.00692	0.0258	CbGeAlD
Lithium—GSK3A—uterus—uterine cancer	0.00669	0.0249	CbGeAlD
Lithium—IMPA2—female gonad—uterine cancer	0.00641	0.0239	CbGeAlD
Lithium—IMPA2—vagina—uterine cancer	0.00637	0.0237	CbGeAlD
Lithium—GSK3B—female gonad—uterine cancer	0.00629	0.0234	CbGeAlD
Lithium—GSK3B—vagina—uterine cancer	0.00625	0.0233	CbGeAlD
Lithium—GSK3A—female reproductive system—uterine cancer	0.00601	0.0224	CbGeAlD
Lithium—GSK3A—female gonad—uterine cancer	0.00547	0.0204	CbGeAlD
Lithium—GSK3A—vagina—uterine cancer	0.00544	0.0203	CbGeAlD
Lithium—IMPA2—lymph node—uterine cancer	0.00412	0.0154	CbGeAlD
Lithium—GSK3B—lymph node—uterine cancer	0.00405	0.0151	CbGeAlD
Lithium—GSK3A—lymph node—uterine cancer	0.00352	0.0131	CbGeAlD
Lithium—Chest discomfort—Etoposide—uterine cancer	0.00148	0.00514	CcSEcCtD
Lithium—Weight increased—Progesterone—uterine cancer	0.00147	0.00508	CcSEcCtD
Lithium—Weight decreased—Progesterone—uterine cancer	0.00146	0.00505	CcSEcCtD
Lithium—Hyperglycaemia—Progesterone—uterine cancer	0.00145	0.00503	CcSEcCtD
Lithium—Drowsiness—Progesterone—uterine cancer	0.00144	0.00497	CcSEcCtD
Lithium—Body temperature increased—Carboplatin—uterine cancer	0.00138	0.00477	CcSEcCtD
Lithium—Lethargy—Dactinomycin—uterine cancer	0.00134	0.00465	CcSEcCtD
Lithium—Blindness—Epirubicin—uterine cancer	0.00133	0.0046	CcSEcCtD
Lithium—Weight increased—Medroxyprogesterone Acetate—uterine cancer	0.00133	0.0046	CcSEcCtD
Lithium—Weight decreased—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00457	CcSEcCtD
Lithium—Hyperglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00456	CcSEcCtD
Lithium—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.0013	0.00451	CcSEcCtD
Lithium—Blindness—Doxorubicin—uterine cancer	0.00123	0.00426	CcSEcCtD
Lithium—Tinnitus—Progesterone—uterine cancer	0.0012	0.00416	CcSEcCtD
Lithium—Optic neuritis—Epirubicin—uterine cancer	0.0012	0.00414	CcSEcCtD
Lithium—Bradycardia—Medroxyprogesterone Acetate—uterine cancer	0.00119	0.00412	CcSEcCtD
Lithium—Psoriasis—Epirubicin—uterine cancer	0.00117	0.00406	CcSEcCtD
Lithium—Folliculitis—Epirubicin—uterine cancer	0.00117	0.00406	CcSEcCtD
Lithium—Alopecia—Progesterone—uterine cancer	0.00114	0.00395	CcSEcCtD
Lithium—Optic neuritis—Doxorubicin—uterine cancer	0.00111	0.00383	CcSEcCtD
Lithium—Flatulence—Progesterone—uterine cancer	0.00111	0.00383	CcSEcCtD
Lithium—Tinnitus—Medroxyprogesterone Acetate—uterine cancer	0.00109	0.00377	CcSEcCtD
Lithium—Folliculitis—Doxorubicin—uterine cancer	0.00108	0.00375	CcSEcCtD
Lithium—Psoriasis—Doxorubicin—uterine cancer	0.00108	0.00375	CcSEcCtD
Lithium—Swelling—Etoposide—uterine cancer	0.00108	0.00374	CcSEcCtD
Lithium—Hypercalcaemia—Epirubicin—uterine cancer	0.00106	0.00367	CcSEcCtD
Lithium—Vision blurred—Progesterone—uterine cancer	0.00106	0.00366	CcSEcCtD
Lithium—Tremor—Progesterone—uterine cancer	0.00105	0.00364	CcSEcCtD
Lithium—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.00103	0.00357	CcSEcCtD
Lithium—Nystagmus—Epirubicin—uterine cancer	0.00103	0.00357	CcSEcCtD
Lithium—Angioedema—Progesterone—uterine cancer	0.00103	0.00355	CcSEcCtD
Lithium—Vertigo—Progesterone—uterine cancer	0.00101	0.00349	CcSEcCtD
Lithium—Syncope—Progesterone—uterine cancer	0.00101	0.00349	CcSEcCtD
Lithium—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.001	0.00347	CcSEcCtD
Lithium—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.000996	0.00345	CcSEcCtD
Lithium—Loss of consciousness—Progesterone—uterine cancer	0.000986	0.00342	CcSEcCtD
Lithium—Albuminuria—Epirubicin—uterine cancer	0.000986	0.00341	CcSEcCtD
Lithium—Hypercalcaemia—Doxorubicin—uterine cancer	0.00098	0.0034	CcSEcCtD
Lithium—Convulsion—Progesterone—uterine cancer	0.000972	0.00337	CcSEcCtD
Lithium—Scotoma—Epirubicin—uterine cancer	0.000969	0.00336	CcSEcCtD
Lithium—Arthralgia—Progesterone—uterine cancer	0.000955	0.00331	CcSEcCtD
Lithium—Nystagmus—Doxorubicin—uterine cancer	0.000954	0.0033	CcSEcCtD
Lithium—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.000953	0.0033	CcSEcCtD
Lithium—Skin ulcer—Epirubicin—uterine cancer	0.000945	0.00327	CcSEcCtD
Lithium—Discomfort—Progesterone—uterine cancer	0.000944	0.00327	CcSEcCtD
Lithium—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.000934	0.00324	CcSEcCtD
Lithium—Dry mouth—Progesterone—uterine cancer	0.000934	0.00324	CcSEcCtD
Lithium—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.000929	0.00322	CcSEcCtD
Lithium—Confusional state—Progesterone—uterine cancer	0.000923	0.0032	CcSEcCtD
Lithium—Oedema—Progesterone—uterine cancer	0.000916	0.00317	CcSEcCtD
Lithium—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.000914	0.00316	CcSEcCtD
Lithium—Albuminuria—Doxorubicin—uterine cancer	0.000912	0.00316	CcSEcCtD
Lithium—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.000912	0.00316	CcSEcCtD
Lithium—Glycosuria—Epirubicin—uterine cancer	0.000909	0.00315	CcSEcCtD
Lithium—Shock—Progesterone—uterine cancer	0.000901	0.00312	CcSEcCtD
Lithium—Scotoma—Doxorubicin—uterine cancer	0.000897	0.00311	CcSEcCtD
Lithium—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.000894	0.0031	CcSEcCtD
Lithium—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.000881	0.00305	CcSEcCtD
Lithium—Skin ulcer—Doxorubicin—uterine cancer	0.000875	0.00303	CcSEcCtD
Lithium—Anorexia—Progesterone—uterine cancer	0.000873	0.00302	CcSEcCtD
Lithium—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000866	0.003	CcSEcCtD
Lithium—Hypotension—Progesterone—uterine cancer	0.000856	0.00296	CcSEcCtD
Lithium—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000855	0.00296	CcSEcCtD
Lithium—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.000847	0.00293	CcSEcCtD
Lithium—Glycosuria—Doxorubicin—uterine cancer	0.000841	0.00291	CcSEcCtD
Lithium—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.000837	0.0029	CcSEcCtD
Lithium—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000834	0.00289	CcSEcCtD
Lithium—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00083	0.00287	CcSEcCtD
Lithium—Shock—Medroxyprogesterone Acetate—uterine cancer	0.000816	0.00283	CcSEcCtD
Lithium—Somnolence—Progesterone—uterine cancer	0.000814	0.00282	CcSEcCtD
Lithium—Dyspepsia—Progesterone—uterine cancer	0.000806	0.00279	CcSEcCtD
Lithium—Alopecia—Dactinomycin—uterine cancer	0.000805	0.00279	CcSEcCtD
Lithium—Oliguria—Epirubicin—uterine cancer	0.000799	0.00277	CcSEcCtD
Lithium—Decreased appetite—Progesterone—uterine cancer	0.000796	0.00276	CcSEcCtD
Lithium—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000791	0.00274	CcSEcCtD
Lithium—Fatigue—Progesterone—uterine cancer	0.00079	0.00273	CcSEcCtD
Lithium—Dysarthria—Epirubicin—uterine cancer	0.000778	0.0027	CcSEcCtD
Lithium—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000775	0.00269	CcSEcCtD
Lithium—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000756	0.00262	CcSEcCtD
Lithium—Feeling abnormal—Progesterone—uterine cancer	0.000755	0.00261	CcSEcCtD
Lithium—Coordination abnormal—Epirubicin—uterine cancer	0.00075	0.0026	CcSEcCtD
Lithium—Gastrointestinal pain—Progesterone—uterine cancer	0.000749	0.00259	CcSEcCtD
Lithium—Oliguria—Doxorubicin—uterine cancer	0.000739	0.00256	CcSEcCtD
Lithium—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000738	0.00256	CcSEcCtD
Lithium—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000731	0.00253	CcSEcCtD
Lithium—Abdominal pain—Progesterone—uterine cancer	0.000724	0.00251	CcSEcCtD
Lithium—Body temperature increased—Progesterone—uterine cancer	0.000724	0.00251	CcSEcCtD
Lithium—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000721	0.0025	CcSEcCtD
Lithium—Dysarthria—Doxorubicin—uterine cancer	0.00072	0.00249	CcSEcCtD
Lithium—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000715	0.00248	CcSEcCtD
Lithium—Salivary hypersecretion—Epirubicin—uterine cancer	0.000715	0.00248	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—uterine cancer	0.000694	0.0024	CcSEcCtD
Lithium—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000684	0.00237	CcSEcCtD
Lithium—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000679	0.00235	CcSEcCtD
Lithium—Coma—Epirubicin—uterine cancer	0.000673	0.00233	CcSEcCtD
Lithium—Discomfort—Dactinomycin—uterine cancer	0.000667	0.00231	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—uterine cancer	0.000661	0.00229	CcSEcCtD
Lithium—Asthenia—Progesterone—uterine cancer	0.000657	0.00228	CcSEcCtD
Lithium—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000656	0.00227	CcSEcCtD
Lithium—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000656	0.00227	CcSEcCtD
Lithium—Oedema—Dactinomycin—uterine cancer	0.000647	0.00224	CcSEcCtD
Lithium—Hypertonia—Epirubicin—uterine cancer	0.000645	0.00223	CcSEcCtD
Lithium—Diarrhoea—Progesterone—uterine cancer	0.000627	0.00217	CcSEcCtD
Lithium—Coma—Doxorubicin—uterine cancer	0.000622	0.00216	CcSEcCtD
Lithium—Anorexia—Dactinomycin—uterine cancer	0.000617	0.00214	CcSEcCtD
Lithium—Dizziness—Progesterone—uterine cancer	0.000606	0.0021	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—uterine cancer	0.000597	0.00207	CcSEcCtD
Lithium—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000595	0.00206	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00059	0.00204	CcSEcCtD
Lithium—Alopecia—Etoposide—uterine cancer	0.000583	0.00202	CcSEcCtD
Lithium—Vomiting—Progesterone—uterine cancer	0.000582	0.00202	CcSEcCtD
Lithium—Rash—Progesterone—uterine cancer	0.000577	0.002	CcSEcCtD
Lithium—Dermatitis—Progesterone—uterine cancer	0.000577	0.002	CcSEcCtD
Lithium—Headache—Progesterone—uterine cancer	0.000574	0.00199	CcSEcCtD
Lithium—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000568	0.00197	CcSEcCtD
Lithium—Decreased appetite—Dactinomycin—uterine cancer	0.000563	0.00195	CcSEcCtD
Lithium—Dysgeusia—Etoposide—uterine cancer	0.000562	0.00195	CcSEcCtD
Lithium—Fatigue—Dactinomycin—uterine cancer	0.000558	0.00193	CcSEcCtD
Lithium—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000549	0.0019	CcSEcCtD
Lithium—Lethargy—Epirubicin—uterine cancer	0.000545	0.00189	CcSEcCtD
Lithium—Nausea—Progesterone—uterine cancer	0.000544	0.00188	CcSEcCtD
Lithium—Feeling abnormal—Dactinomycin—uterine cancer	0.000533	0.00185	CcSEcCtD
Lithium—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000529	0.00183	CcSEcCtD
Lithium—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000528	0.00183	CcSEcCtD
Lithium—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000523	0.00181	CcSEcCtD
Lithium—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000523	0.00181	CcSEcCtD
Lithium—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00052	0.0018	CcSEcCtD
Lithium—Vertigo—Etoposide—uterine cancer	0.000516	0.00179	CcSEcCtD
Lithium—Body temperature increased—Dactinomycin—uterine cancer	0.000512	0.00177	CcSEcCtD
Lithium—Abdominal pain—Dactinomycin—uterine cancer	0.000512	0.00177	CcSEcCtD
Lithium—Loss of consciousness—Etoposide—uterine cancer	0.000505	0.00175	CcSEcCtD
Lithium—Lethargy—Doxorubicin—uterine cancer	0.000505	0.00175	CcSEcCtD
Lithium—Ataxia—Epirubicin—uterine cancer	0.000502	0.00174	CcSEcCtD
Lithium—Convulsion—Etoposide—uterine cancer	0.000497	0.00172	CcSEcCtD
Lithium—Dehydration—Epirubicin—uterine cancer	0.000497	0.00172	CcSEcCtD
Lithium—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000493	0.00171	CcSEcCtD
Lithium—Dry skin—Epirubicin—uterine cancer	0.00049	0.0017	CcSEcCtD
Lithium—Discomfort—Etoposide—uterine cancer	0.000483	0.00167	CcSEcCtD
Lithium—Gastritis—Epirubicin—uterine cancer	0.000473	0.00164	CcSEcCtD
Lithium—Confusional state—Etoposide—uterine cancer	0.000472	0.00164	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—uterine cancer	0.000471	0.00163	CcSEcCtD
Lithium—Ataxia—Doxorubicin—uterine cancer	0.000465	0.00161	CcSEcCtD
Lithium—Asthenia—Dactinomycin—uterine cancer	0.000464	0.00161	CcSEcCtD
Lithium—Dehydration—Doxorubicin—uterine cancer	0.00046	0.00159	CcSEcCtD
Lithium—Dry skin—Doxorubicin—uterine cancer	0.000453	0.00157	CcSEcCtD
Lithium—Anorexia—Etoposide—uterine cancer	0.000447	0.00155	CcSEcCtD
Lithium—Diarrhoea—Dactinomycin—uterine cancer	0.000443	0.00153	CcSEcCtD
Lithium—Hypotension—Etoposide—uterine cancer	0.000438	0.00152	CcSEcCtD
Lithium—Gastritis—Doxorubicin—uterine cancer	0.000438	0.00152	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—uterine cancer	0.000436	0.00151	CcSEcCtD
Lithium—Weight increased—Epirubicin—uterine cancer	0.00042	0.00146	CcSEcCtD
Lithium—Weight decreased—Epirubicin—uterine cancer	0.000418	0.00145	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—uterine cancer	0.000417	0.00144	CcSEcCtD
Lithium—Somnolence—Etoposide—uterine cancer	0.000416	0.00144	CcSEcCtD
Lithium—Drowsiness—Epirubicin—uterine cancer	0.000412	0.00143	CcSEcCtD
Lithium—Vomiting—Dactinomycin—uterine cancer	0.000412	0.00143	CcSEcCtD
Lithium—Rash—Dactinomycin—uterine cancer	0.000408	0.00141	CcSEcCtD
Lithium—Decreased appetite—Etoposide—uterine cancer	0.000407	0.00141	CcSEcCtD
Lithium—Fatigue—Etoposide—uterine cancer	0.000404	0.0014	CcSEcCtD
Lithium—Weight increased—Doxorubicin—uterine cancer	0.000389	0.00135	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—uterine cancer	0.000387	0.00134	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—uterine cancer	0.000386	0.00134	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—uterine cancer	0.000385	0.00134	CcSEcCtD
Lithium—Nausea—Dactinomycin—uterine cancer	0.000385	0.00133	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—uterine cancer	0.000383	0.00133	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—uterine cancer	0.000381	0.00132	CcSEcCtD
Lithium—Bradycardia—Epirubicin—uterine cancer	0.000376	0.0013	CcSEcCtD
Lithium—Abdominal pain—Etoposide—uterine cancer	0.00037	0.00128	CcSEcCtD
Lithium—Body temperature increased—Etoposide—uterine cancer	0.00037	0.00128	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—uterine cancer	0.000348	0.00121	CcSEcCtD
Lithium—Tinnitus—Epirubicin—uterine cancer	0.000345	0.00119	CcSEcCtD
Lithium—Asthenia—Etoposide—uterine cancer	0.000336	0.00116	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—uterine cancer	0.00033	0.00114	CcSEcCtD
Lithium—Alopecia—Epirubicin—uterine cancer	0.000327	0.00113	CcSEcCtD
Lithium—Diarrhoea—Etoposide—uterine cancer	0.000321	0.00111	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—uterine cancer	0.000319	0.0011	CcSEcCtD
Lithium—Flatulence—Epirubicin—uterine cancer	0.000317	0.0011	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—uterine cancer	0.000315	0.00109	CcSEcCtD
Lithium—Dizziness—Etoposide—uterine cancer	0.00031	0.00107	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—uterine cancer	0.000306	0.00106	CcSEcCtD
Lithium—Vision blurred—Epirubicin—uterine cancer	0.000303	0.00105	CcSEcCtD
Lithium—Alopecia—Doxorubicin—uterine cancer	0.000302	0.00105	CcSEcCtD
Lithium—Vomiting—Etoposide—uterine cancer	0.000298	0.00103	CcSEcCtD
Lithium—Agitation—Epirubicin—uterine cancer	0.000296	0.00102	CcSEcCtD
Lithium—Rash—Etoposide—uterine cancer	0.000295	0.00102	CcSEcCtD
Lithium—Dermatitis—Etoposide—uterine cancer	0.000295	0.00102	CcSEcCtD
Lithium—Headache—Etoposide—uterine cancer	0.000293	0.00102	CcSEcCtD
Lithium—Flatulence—Doxorubicin—uterine cancer	0.000293	0.00102	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—uterine cancer	0.000292	0.00101	CcSEcCtD
Lithium—Vertigo—Epirubicin—uterine cancer	0.000289	0.001	CcSEcCtD
Lithium—Syncope—Epirubicin—uterine cancer	0.000289	0.000999	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—uterine cancer	0.000283	0.00098	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—uterine cancer	0.000281	0.000972	CcSEcCtD
Lithium—Convulsion—Epirubicin—uterine cancer	0.000279	0.000966	CcSEcCtD
Lithium—Nausea—Etoposide—uterine cancer	0.000278	0.000964	CcSEcCtD
Lithium—Arthralgia—Epirubicin—uterine cancer	0.000274	0.000949	CcSEcCtD
Lithium—Agitation—Doxorubicin—uterine cancer	0.000274	0.000948	CcSEcCtD
Lithium—Discomfort—Epirubicin—uterine cancer	0.000271	0.000937	CcSEcCtD
Lithium—Dry mouth—Epirubicin—uterine cancer	0.000268	0.000928	CcSEcCtD
Lithium—Vertigo—Doxorubicin—uterine cancer	0.000268	0.000926	CcSEcCtD
Lithium—Syncope—Doxorubicin—uterine cancer	0.000267	0.000925	CcSEcCtD
Lithium—Confusional state—Epirubicin—uterine cancer	0.000265	0.000917	CcSEcCtD
Lithium—Oedema—Epirubicin—uterine cancer	0.000263	0.00091	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—uterine cancer	0.000262	0.000906	CcSEcCtD
Lithium—Shock—Epirubicin—uterine cancer	0.000258	0.000895	CcSEcCtD
Lithium—Convulsion—Doxorubicin—uterine cancer	0.000258	0.000893	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—uterine cancer	0.000253	0.000878	CcSEcCtD
Lithium—Discomfort—Doxorubicin—uterine cancer	0.00025	0.000867	CcSEcCtD
Lithium—Anorexia—Epirubicin—uterine cancer	0.00025	0.000867	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—uterine cancer	0.000248	0.000859	CcSEcCtD
Lithium—Hypotension—Epirubicin—uterine cancer	0.000245	0.00085	CcSEcCtD
Lithium—Confusional state—Doxorubicin—uterine cancer	0.000245	0.000849	CcSEcCtD
Lithium—Oedema—Doxorubicin—uterine cancer	0.000243	0.000842	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000239	0.000829	CcSEcCtD
Lithium—Shock—Doxorubicin—uterine cancer	0.000239	0.000828	CcSEcCtD
Lithium—Somnolence—Epirubicin—uterine cancer	0.000233	0.000809	CcSEcCtD
Lithium—Anorexia—Doxorubicin—uterine cancer	0.000232	0.000802	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—uterine cancer	0.000231	0.000801	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—uterine cancer	0.000228	0.000791	CcSEcCtD
Lithium—Hypotension—Doxorubicin—uterine cancer	0.000227	0.000786	CcSEcCtD
Lithium—Fatigue—Epirubicin—uterine cancer	0.000226	0.000784	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000221	0.000767	CcSEcCtD
Lithium—Feeling abnormal—Epirubicin—uterine cancer	0.000216	0.00075	CcSEcCtD
Lithium—Somnolence—Doxorubicin—uterine cancer	0.000216	0.000748	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—uterine cancer	0.000215	0.000744	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—uterine cancer	0.000214	0.000741	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—uterine cancer	0.000211	0.000732	CcSEcCtD
Lithium—Fatigue—Doxorubicin—uterine cancer	0.000209	0.000726	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—uterine cancer	0.000208	0.000719	CcSEcCtD
Lithium—Body temperature increased—Epirubicin—uterine cancer	0.000208	0.000719	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—uterine cancer	0.0002	0.000694	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000199	0.000688	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—uterine cancer	0.000192	0.000665	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—uterine cancer	0.000192	0.000665	CcSEcCtD
Lithium—Asthenia—Epirubicin—uterine cancer	0.000188	0.000653	CcSEcCtD
Lithium—Diarrhoea—Epirubicin—uterine cancer	0.00018	0.000622	CcSEcCtD
Lithium—Asthenia—Doxorubicin—uterine cancer	0.000174	0.000604	CcSEcCtD
Lithium—Dizziness—Epirubicin—uterine cancer	0.000174	0.000601	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—CDKN1B—uterine cancer	0.000168	0.000388	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—uterine cancer	0.000167	0.000387	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—HRAS—uterine cancer	0.000167	0.000386	CbGpPWpGaD
Lithium—Vomiting—Epirubicin—uterine cancer	0.000167	0.000578	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—uterine cancer	0.000166	0.000576	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	0.000166	0.000385	CbGpPWpGaD
Lithium—Rash—Epirubicin—uterine cancer	0.000166	0.000573	CcSEcCtD
Lithium—Dermatitis—Epirubicin—uterine cancer	0.000165	0.000573	CcSEcCtD
Lithium—Headache—Epirubicin—uterine cancer	0.000165	0.00057	CcSEcCtD
Lithium—GSK3B—Signaling by WNT in cancer—EP300—uterine cancer	0.000164	0.00038	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—FGFR2—uterine cancer	0.000164	0.00038	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ERBB2—uterine cancer	0.000164	0.000379	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—AKT1—uterine cancer	0.000163	0.000378	CbGpPWpGaD
Lithium—GSK3B—Disease—DCN—uterine cancer	0.000163	0.000378	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KRAS—uterine cancer	0.000161	0.000372	CbGpPWpGaD
Lithium—Dizziness—Doxorubicin—uterine cancer	0.000161	0.000557	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—RNF43—uterine cancer	0.000161	0.000371	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KRAS—uterine cancer	0.00016	0.000371	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—HRAS—uterine cancer	0.00016	0.000371	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MET—uterine cancer	0.00016	0.00037	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTEN—uterine cancer	0.00016	0.00037	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—PIK3CA—uterine cancer	0.00016	0.00037	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—PIK3CA—uterine cancer	0.00016	0.00037	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—PIK3CA—uterine cancer	0.00016	0.00037	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—HRAS—uterine cancer	0.000159	0.000369	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDH1—uterine cancer	0.000159	0.000368	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—uterine cancer	0.000159	0.000367	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—PIK3CA—uterine cancer	0.000158	0.000366	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—HRAS—uterine cancer	0.000158	0.000365	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—FGFR2—uterine cancer	0.000158	0.000365	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—uterine cancer	0.000157	0.000364	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—PIK3CA—uterine cancer	0.000157	0.000363	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—EP300—uterine cancer	0.000157	0.000363	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—AKT1—uterine cancer	0.000157	0.000362	CbGpPWpGaD
Lithium—GSK3B—Immune System—IRF1—uterine cancer	0.000157	0.000362	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	0.000156	0.000362	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—PIK3CA—uterine cancer	0.000156	0.000362	CbGpPWpGaD
Lithium—Nausea—Epirubicin—uterine cancer	0.000156	0.00054	CcSEcCtD
Lithium—GSK3A—Immune System—SOCS3—uterine cancer	0.000155	0.00036	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—uterine cancer	0.000155	0.000358	CbGpPWpGaD
Lithium—Vomiting—Doxorubicin—uterine cancer	0.000154	0.000535	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—PTEN—uterine cancer	0.000154	0.000357	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—uterine cancer	0.000154	0.000356	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—AKT1—uterine cancer	0.000154	0.000356	CbGpPWpGaD
Lithium—Rash—Doxorubicin—uterine cancer	0.000153	0.000531	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—uterine cancer	0.000153	0.00053	CcSEcCtD
Lithium—IMPA2—Metabolism—EP300—uterine cancer	0.000152	0.000353	CbGpPWpGaD
Lithium—Headache—Doxorubicin—uterine cancer	0.000152	0.000527	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—PIK3CA—uterine cancer	0.000151	0.000349	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—AKT1—uterine cancer	0.00015	0.000347	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—VEGFA—uterine cancer	0.000149	0.000344	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—PIK3CA—uterine cancer	0.000148	0.000342	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—uterine cancer	0.000148	0.000342	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—uterine cancer	0.000148	0.000342	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—uterine cancer	0.000148	0.000342	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—AKT1—uterine cancer	0.000147	0.000341	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—PIK3CA—uterine cancer	0.000147	0.000341	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—INHBA—uterine cancer	0.000147	0.00034	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—uterine cancer	0.000147	0.000339	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CCL2—uterine cancer	0.000146	0.000339	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—CTNNB1—uterine cancer	0.000146	0.000337	CbGpPWpGaD
Lithium—GSK3B—Disease—AKR1C3—uterine cancer	0.000145	0.000336	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—uterine cancer	0.000145	0.000336	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—HRAS—uterine cancer	0.000145	0.000335	CbGpPWpGaD
Lithium—Nausea—Doxorubicin—uterine cancer	0.000144	0.0005	CcSEcCtD
Lithium—IMPA1—Metabolism—PTEN—uterine cancer	0.000142	0.00033	CbGpPWpGaD
Lithium—GSK3B—Disease—HMGA1—uterine cancer	0.000142	0.000328	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—PIK3CA—uterine cancer	0.000142	0.000327	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—AKT1—uterine cancer	0.000142	0.000327	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—AKT1—uterine cancer	0.000141	0.000326	CbGpPWpGaD
Lithium—GSK3B—Immune System—FBXW7—uterine cancer	0.00014	0.000325	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—AKT1—uterine cancer	0.00014	0.000324	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—HRAS—uterine cancer	0.00014	0.000323	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB2—uterine cancer	0.00014	0.000323	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—uterine cancer	0.00014	0.000323	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—AKT1—uterine cancer	0.000139	0.000323	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—AKT1—uterine cancer	0.000139	0.000321	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKR1C3—uterine cancer	0.000138	0.000319	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NRAS—uterine cancer	0.000138	0.000319	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN2B—uterine cancer	0.000137	0.000318	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—HRAS—uterine cancer	0.000137	0.000317	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—AKT1—uterine cancer	0.000137	0.000316	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—HRAS—uterine cancer	0.000136	0.000315	CbGpPWpGaD
Lithium—IMPA1—Metabolism—EP300—uterine cancer	0.000136	0.000314	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—EP300—uterine cancer	0.000136	0.000314	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PGR—uterine cancer	0.000134	0.00031	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB2—uterine cancer	0.000134	0.00031	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKR1C1—uterine cancer	0.000132	0.000306	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	0.000131	0.000303	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—AKT1—uterine cancer	0.000131	0.000302	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	0.000131	0.000302	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—AKT1—uterine cancer	0.000131	0.000302	CbGpPWpGaD
Lithium—GSK3A—Immune System—FGFR2—uterine cancer	0.00013	0.0003	CbGpPWpGaD
Lithium—GSK3B—Disease—FBXW7—uterine cancer	0.00013	0.0003	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—uterine cancer	0.000129	0.000299	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDKN1B—uterine cancer	0.000129	0.000299	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—uterine cancer	0.000128	0.000297	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—YWHAE—uterine cancer	0.000128	0.000296	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—AKT1—uterine cancer	0.000128	0.000295	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—uterine cancer	0.000126	0.000292	CbGpPWpGaD
Lithium—GSK3A—Disease—SMAD3—uterine cancer	0.000125	0.00029	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—uterine cancer	0.000125	0.000288	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1B—uterine cancer	0.000124	0.000287	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—uterine cancer	0.000123	0.000285	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FBXW7—uterine cancer	0.000123	0.000284	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—uterine cancer	0.000122	0.000283	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—uterine cancer	0.000121	0.00028	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—uterine cancer	0.00012	0.000278	CbGpPWpGaD
Lithium—GSK3A—Disease—FGFR2—uterine cancer	0.00012	0.000277	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PTEN—uterine cancer	0.000119	0.000276	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—uterine cancer	0.000118	0.000274	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDH1—uterine cancer	0.000117	0.000272	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—uterine cancer	0.000117	0.00027	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CXCL8—uterine cancer	0.000116	0.000268	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	0.000116	0.000268	CbGpPWpGaD
Lithium—GSK3A—Disease—MTHFR—uterine cancer	0.000115	0.000266	CbGpPWpGaD
Lithium—GSK3B—Immune System—SOCS3—uterine cancer	0.000115	0.000266	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PTEN—uterine cancer	0.000114	0.000265	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EP300—uterine cancer	0.000114	0.000263	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PIK3CA—uterine cancer	0.000113	0.000261	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—uterine cancer	0.000112	0.00026	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—uterine cancer	0.000111	0.000256	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PIK3CA—uterine cancer	0.000109	0.000252	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STK11—uterine cancer	0.000107	0.000248	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—uterine cancer	0.000107	0.000248	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—uterine cancer	0.000107	0.000248	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—uterine cancer	0.000107	0.000247	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—uterine cancer	0.000106	0.000246	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—uterine cancer	0.000103	0.000239	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—uterine cancer	0.000102	0.000237	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—uterine cancer	0.000102	0.000236	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKR1C3—uterine cancer	0.000102	0.000235	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN2B—uterine cancer	0.000101	0.000235	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—uterine cancer	0.000101	0.000233	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PIK3CA—uterine cancer	0.000101	0.000233	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SOCS3—uterine cancer	0.0001	0.000232	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—uterine cancer	9.94e-05	0.00023	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PGR—uterine cancer	9.92e-05	0.000229	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—uterine cancer	9.91e-05	0.000229	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDH1—uterine cancer	9.64e-05	0.000223	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN2B—uterine cancer	9.62e-05	0.000223	CbGpPWpGaD
Lithium—GSK3B—Immune System—FGFR2—uterine cancer	9.57e-05	0.000221	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1B—uterine cancer	9.56e-05	0.000221	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EP300—uterine cancer	9.5e-05	0.00022	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—YWHAE—uterine cancer	9.46e-05	0.000219	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1R—uterine cancer	9.34e-05	0.000216	CbGpPWpGaD
Lithium—GSK3B—Disease—SMAD3—uterine cancer	9.27e-05	0.000214	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—uterine cancer	9.21e-05	0.000213	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1B—uterine cancer	9.18e-05	0.000212	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—uterine cancer	9.15e-05	0.000212	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—uterine cancer	9.12e-05	0.000211	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FBXW7—uterine cancer	9.07e-05	0.00021	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—uterine cancer	9.03e-05	0.000209	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—uterine cancer	9e-05	0.000208	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—uterine cancer	8.89e-05	0.000206	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—uterine cancer	8.89e-05	0.000206	CbGpPWpGaD
Lithium—GSK3B—Disease—FGFR2—uterine cancer	8.84e-05	0.000204	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—uterine cancer	8.8e-05	0.000204	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—uterine cancer	8.78e-05	0.000203	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SMAD3—uterine cancer	8.78e-05	0.000203	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—uterine cancer	8.51e-05	0.000197	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—uterine cancer	8.45e-05	0.000196	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—uterine cancer	8.4e-05	0.000194	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EP300—uterine cancer	8.39e-05	0.000194	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGFR2—uterine cancer	8.38e-05	0.000194	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—uterine cancer	8.21e-05	0.00019	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—uterine cancer	8.19e-05	0.000189	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—uterine cancer	8.14e-05	0.000188	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—uterine cancer	8.07e-05	0.000187	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STK11—uterine cancer	7.93e-05	0.000183	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—uterine cancer	7.85e-05	0.000182	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—uterine cancer	7.77e-05	0.00018	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—uterine cancer	7.65e-05	0.000177	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—uterine cancer	7.54e-05	0.000174	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1B—uterine cancer	7.53e-05	0.000174	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—uterine cancer	7.51e-05	0.000174	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—uterine cancer	7.47e-05	0.000173	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SOCS3—uterine cancer	7.42e-05	0.000172	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ESR1—uterine cancer	7.17e-05	0.000166	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—uterine cancer	7.13e-05	0.000165	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—uterine cancer	7.12e-05	0.000165	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN2B—uterine cancer	7.11e-05	0.000164	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1B—uterine cancer	6.96e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—uterine cancer	6.94e-05	0.00016	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1R—uterine cancer	6.9e-05	0.00016	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—uterine cancer	6.86e-05	0.000159	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—uterine cancer	6.76e-05	0.000156	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—uterine cancer	6.62e-05	0.000153	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—uterine cancer	6.59e-05	0.000152	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—uterine cancer	6.57e-05	0.000152	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—uterine cancer	6.5e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—uterine cancer	6.49e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMAD3—uterine cancer	6.49e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—uterine cancer	6.41e-05	0.000148	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCL2—uterine cancer	6.31e-05	0.000146	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—uterine cancer	6.21e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGFR2—uterine cancer	6.19e-05	0.000143	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—uterine cancer	6.19e-05	0.000143	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—uterine cancer	6.11e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—uterine cancer	6.01e-05	0.000139	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—uterine cancer	5.96e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—uterine cancer	5.74e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—uterine cancer	5.74e-05	0.000133	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—uterine cancer	5.71e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1B—uterine cancer	5.57e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—uterine cancer	5.55e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—uterine cancer	5.52e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—uterine cancer	5.33e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ESR1—uterine cancer	5.3e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—uterine cancer	5.26e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—uterine cancer	5.26e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1B—uterine cancer	5.14e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—uterine cancer	5.13e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—uterine cancer	5.07e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—uterine cancer	4.99e-05	0.000115	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—uterine cancer	4.92e-05	0.000114	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—uterine cancer	4.89e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—uterine cancer	4.89e-05	0.000113	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1B—uterine cancer	4.87e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—uterine cancer	4.87e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—uterine cancer	4.86e-05	0.000112	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—uterine cancer	4.73e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL2—uterine cancer	4.66e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—uterine cancer	4.6e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—uterine cancer	4.57e-05	0.000106	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—uterine cancer	4.53e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—uterine cancer	4.52e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—uterine cancer	4.51e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—uterine cancer	4.49e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—uterine cancer	4.28e-05	9.9e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—uterine cancer	4.22e-05	9.77e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—uterine cancer	4.18e-05	9.67e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—uterine cancer	4.05e-05	9.37e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—uterine cancer	4e-05	9.26e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—uterine cancer	4e-05	9.25e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—uterine cancer	3.94e-05	9.11e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—uterine cancer	3.89e-05	8.99e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—uterine cancer	3.69e-05	8.54e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—uterine cancer	3.69e-05	8.53e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—uterine cancer	3.63e-05	8.41e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—uterine cancer	3.62e-05	8.37e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1B—uterine cancer	3.6e-05	8.33e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—uterine cancer	3.44e-05	7.97e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—uterine cancer	3.4e-05	7.87e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—uterine cancer	3.35e-05	7.74e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—uterine cancer	3.34e-05	7.72e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—uterine cancer	3.31e-05	7.67e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—uterine cancer	3.16e-05	7.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—uterine cancer	3.16e-05	7.31e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—uterine cancer	3.09e-05	7.15e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—uterine cancer	3.06e-05	7.08e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—uterine cancer	2.99e-05	6.93e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—uterine cancer	2.96e-05	6.84e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—uterine cancer	2.95e-05	6.83e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—uterine cancer	2.93e-05	6.77e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—uterine cancer	2.73e-05	6.31e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—uterine cancer	2.58e-05	5.98e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—uterine cancer	2.55e-05	5.89e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—uterine cancer	2.34e-05	5.41e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—uterine cancer	2.26e-05	5.23e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—uterine cancer	2.16e-05	5e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—uterine cancer	1.91e-05	4.42e-05	CbGpPWpGaD
